SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Summit Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$15.57+0.94 (+6.43%)
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Summit Therapeutics has not reported a dividend
No dividend per share appears in Summit Therapeutics's annual filings since fiscal 2016.